在2型糖尿病中与杜拉古类和功能相关的结果:一轮复习后期分析
Fady T Botros1, Hertzel C Gerstein2, Raleigh Malik1
1Eli Lilly and Company, Indianapolis, IN.
Diabetes care
|June 21, 2023
概括
杜拉古 (DU) 显著减缓了2型糖尿病患者的功能衰退,降低了主要结局的风险. 这项研究强调了 DU 的重要性.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
背景情况:
- REWIND试验证明了杜拉格卢提德对综合性结局的益处,包括2型糖尿病患者新发性宏蛋白尿症.
- 本次特异性分析侧重于与功能相关的结果,不包括新发的宏蛋白尿症.
研究的目的:
- 在REWIND试验中评估杜拉格卢 (DU) 对功能相关结果的作用,不包括新发性宏相蛋白尿症.
- 评估DU对持续估计膜过率 (eGFR) 降低,末期病和死亡的影响.
主要方法:
- 对4949名接受DU和4952名接受安慰剂的参与者进行了治疗意图分析.
- 关键结果包括复合功能相关事件发生的时间 (≥40%持续的EGFR下降,末期病或死亡) 和年平均EGFR斜率.
- 根据基线尿白蛋白与肌素比率 (UACR) 和eGFR.进行了亚组分析.
主要成果:
- 与功能相关的综合结局发生的频率较低,与安慰剂相比 (HR 0.75,P = 0.004).
- 持续的eGFR下降≥40%在DU组中较少发生 (HR 0.72,P = 0.002).
- 与安慰剂 (-1.56 mL/min/1.73 m2/year) 相比,平均每年eGFR下降幅度较低,在DU (-1.37 mL/min/1.73 m2/year) 与安慰剂 (-1.56 mL/min/1.73 m2/year) 相比,在各子组的结果类似.
结论:
- 杜拉格卢提德显示,与功能相关的结果的危险性降低了25%.
- 这些发现表明,杜拉格卢提德有可能延迟或减缓糖尿病病的进展.
- 根据基线UACR和eGFR定义的各个子组,这些益处是一致的.
相关概念视频
01:24Glucagon-like Receptor Agonists
369
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
369
01:23Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
01:22Diabetes Mellitus: Type 2 and Gestational
2.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
01:06Oral Hypoglycemic Agents: Glinides
190
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
190
01:16Insulin: Dosing Regimen and Adverse Effects
215
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
215